Clinical Materials and Methods

Patient Population
After institutional review board approval, we retrospectively reviewed all aneurysm cases treated with coil insertion in the last 2 years. This consisted of 193 aneurysm coil treatment procedures in 158 patients. Thirty-eight of these procedures were not included due to the absence of a postprocedure MR image, leaving 155 cases in 132 patients. The patients' demographic characteristics were documented and records reviewed for abnormalities on DW imaging seen on postprocedure MR images, intraoperative thrombus formation, clinical signs of stroke, and elective as opposed to SAH presentation. The aneurysm size was documented from the operative notes or preoperative computed tomography angiograms.
Of the 155 aneurysms in 132 patients, 66 (43%) were treated with coils, 45 (29%) had stent-assisted coil insertion, 33 (21%) underwent balloon remodeling, and in 11 (7%) stents were placed after balloon remodeling. There were 111 (72%) anterior circulation aneurysms and 44 (28%) of the lesions were located in the posterior circulation. There were 91 female and 41 male patients, and their mean age was 54 years (standard deviation 15 years, range 10-85 years of age). The mean aneurysm size was 7.5 mm (standard deviation 4.7 mm). Sixty-two (40%) of the aneurysms were found in patients with SAH, and 93 (60%) were treated electively.
All patients treated for aneurysms in our institution undergo MR imaging within 2 weeks of treatment, but the majority undergo imaging within 3 days of treatment for a baseline comparison. Postprocedure MR images were reviewed by an independent neuroradiologist for evidence of acute ischemia, which is seen as areas of restricted diffusion on DW imaging in the treated vascular territory. The DW imaging restriction was verified by assessing associated T2 changes. An example of positive DW imaging restriction changes occurring in a treated vascular territory includes a right middle cerebral artery aneurysm treatment with corresponding right frontal lobe DW imaging changes. The DW imaging abnormalities were considered to be incidental if they occurred outside the treated vascular territory.
We also reviewed the operative records for cases in which patients developed intraprocedural thrombus requiring intraarterial thrombolysis administration. Patients who showed evidence of thrombus formation during the procedure received intraarterial thrombolysis with the intraarterial antiplatelet agent abciximab (Reopro).
The records of patients found to have DW imaging changes or who required intraarterial thrombolysis were further reviewed for evidence of a clinically significant stroke; this is defined as any neurological change or loss of function corresponding to the territory in which DW imaging changes are seen. These can represent TIAs, if resolution occurred within 24 hours, or permanent infarction if the neurological deficit remained for longer than 24 hours. Two examples of this may include a dominant middle cerebral artery territory DW imaging change with evidence of transient aphasia, or right anterior cerebral artery territory DW imaging changes with permanent left lower-extremity weakness.
All endovascular procedures were performed after endotracheally induced general anesthesia with sterile operating conditions. The anticoagulation protocol for treatment of aneurysms differs depending on the presentation; that is, whether lesions are ruptured or unruptured. In unruptured aneurysms, the patient is started on heparin therapy to an activated clotting time of at least twice baseline after arterial access is obtained in the femoral artery. Patients who are candidates for stent insertion are placed on a regimen of 75 mg clopidogrel and 325 mg aspirin at least 5 days prior to the surgery. Treatment with clopidogrel is then continued for 3 months and aspirin is continued indefinitely. For patients with a ruptured aneurysm, no heparin is given until blood flow is altered in the aneurysm after the placement of 1-2 coils. If the aneurysm requires balloon remodeling, the patient receives heparin prior to inflation of the balloon. In general, we do not administer antiplatelet medications to patients with ruptured aneurysms, and therefore do not use stents unless necessary.
Statistical analyses assessing the relationship between baseline variables and outcomes were performed using logistic regression analysis with robust standard errors to account for multiple procedures within subjects. Statistical significance was defined as a probability value of Յ 0.05.
Results
Overall, 24% of the cases (37 of 155) showed DW imaging abnormalities within the treated vascular territory. These were seen in 21 (32%) of 66 in the "coil-only" group, 6 (13%) of 45 in the stent-assisted coil insertion group, 8 (24%) of 33 in the balloon remodeling group, and 2 (18%) of 11 in the balloon remodeling and stent placement group (Fig. 2) . The frequency of DW imaging change in the procedure groups was not significantly different (p = 0.17). Diffusion-weighted imaging abnormalities were seen incidentally in other vascular territories in 6% of procedures.
Restricted DW imaging changes were present in 25 (40%) of 62 cases presenting with SAH and only 12 (13%) of 93 electively treated aneurysms. Logistic regression analysis showed a significant difference in DW imaging frequency between groups based on presentation (p Ͻ 0.001). In cases presenting with SAH, DW imaging abnormalities were present in 19 (45%) of 42 coil-only procedures and 6 (43%) of 14 in the balloon remodeling group. No DW imaging abnormalities were present in the coil-and stent-treated group (4 procedures) or in the balloon remodeling and stent placement group (2 procedures). There was a statistically significant difference between patients with and without stent placement (p = 0.034). In cases presenting for elective aneurysm treatment, DW imaging abnormalities were present in 2 (8%) of 24 coil-only procedures, in 6 (15%) of 41 coil insertion and stent placement procedures, in 2 (11%) of 19 balloon remodeling procedures, and in 2 (22%) of 9 of the balloon remodeling and stent placement procedures (Fig. 3) . There was no significant difference between procedure types among patients with elective presentation (p = 0.77).
There was clinical evidence of stroke or TIA in 10 (27%) of 37 patients with DW imaging abnormalities. Seven of these 10 patients presented with SAH. Five patients developed symptoms of TIA, and 5 had persistent deficits. Only 1 patient received intraarterial thrombolysis; this individual also developed a permanent neurological deficit related to an ischemic infarct. However, we were unable to assess 11 of these 37 patients adequately because of the underlying severity of their neurological compromise or inadequate documentation. Intraprocedural thrombus requiring treatment occurred in 10 (6.5%) of 155 cases. This was seen in 6 (10%) of the 60 coil-only cases, in 2 (4.4%) of 45 coil-and stent-treated cases, in 1 (3%) of 33 balloon remodeling cases, and in 1 (9.1%) of 11 balloon remodeling and stent insertion cases. Seven (70%) of these 10 patients presented with SAH. Of these patients, only 4 of 10 developed DW imaging abnormalities, and 1 manifested as a clinically significant stroke.
Discussion
The evidence presented in our report does not support the hypothesis that embolization of aneurysms by using adjunctive devices is more likely to increase the frequency of thromboembolic complications within the treated vessel territory. Rather, the likelihood of DW imaging positivity was far greater in aneurysms treated acutely for SAH (40%) than those treated electively (13%). This has also been observed in a recent study by Cronqvist et al. 5 We
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Frequency of stroke related to endovascular aneurysm treatment found that positive changes within the treated vessel territory were present on DW imaging in 37 (24%) of the 155 aneurysm cases. Furthermore, the greatest numbers of positive results on DW imaging were in patients presenting with SAH and undergoing standard coil embolization without an adjunctive device (45%). Thrombus formation also followed a similar pattern: 70% of patients in whom thrombus developed presented with SAH. Although DW imaging changes were present in 24% of the aneurysms treated, only 8.4% resulted in a clinically evident stroke. None of the patients who required thrombolysis developed clinical evidence for stroke.
Other authors have published the following frequency rates of embolic complications with the use of adjunctive devices. Albayram et al. 1 reported a 20% frequency of DW imaging changes, with balloon-assisted coil embolization performed in 20 cases. This study did not make a clear distinction between SAH and elective presentation, and all patients were treated with the same anticoagulation regimen. The frequency of DW imaging changes was thought to be related to the number of times that the catheter was repositioned. Cottier et al. 3 reported angiographic demonstration of thromboembolic complications in 4% of 49 cases in which balloon-assisted coil embolization was used. Cronqvist et al. 5 performed a prospective study in which they looked at the frequency of DW imaging changes in 40 patients (14 with SAH and 26 with elective procedures) and did find an association with the remodeling technique as well as aneurysm neck size. Soeda et al. 22 reported a 61% frequency of DW imaging changes on 79 electively treated aneurysms. In 20% of treated patients, neurological deterioration developed. These authors also compared the use of balloon assistance to coil-only embolization, finding that there was a statistically significant association between balloon assistance and development of DW imaging changes. A recently completed study by van Rooij et al. 24 evaluating 681 patients treated with ruptured aneurysms demonstrated a frequency of 4.6% of clinically significant thromboembolic events. Balloon assistance was found to be the only risk factor for development of complications. Nevertheless, the study did not compare this to any other procedure variations, such as balloon and stent use. Rordorf et al. 20 demonstrated a 61% frequency of DW imaging change in electively treated patients. These changes were not associated with the number of coils used.
The discrepancy in DW imaging changes for ruptured compared with unruptured aneurysms is interesting and may have many potential causes. One reason for the discrepancy is probably related to differences in the anticoagulation/antiplatelet regimen used. Patients treated electively receive preprocedure clopidogrel and aspirin and then undergo immediate heparinization after arterial access has been obtained. Patients with ruptured aneurysms, however, do not undergo heparinization until blood flow is altered by placement of 1-2 coils and do not routinely receive antiplatelet medications. Bendszus et al. 2 showed in a prospective randomized trial that heparin therapy administered throughout an angiographic session reduces DW imaging events. The higher frequency of DW imaging changes seen in the coil-only group also probably represents some selection bias. Patients presenting with SAH were more likely to be treated with the simplest procedure-coil insertionand therefore the frequency of DW imaging changes is likely to increase. The increase in DW imaging changes could also represent an effect of treatment that has been undertaken in a region of potential vasospasm. The blood flow that is already minimized to a region of the brain may be further compromised by the procedure. Another proposed mechanism may be the development of a hypercoagulable state. Fujii et al. 7 observed that SAH might induce a hypercoagulable state directly proportional to the amount of subarachnoid blood. In our study, however, we did not compare SAH grade to the development of stroke. This is a potential area of interest for further study.
The data support the contention that elective treatment carries less risk of thromboembolic events than nonelective treatment. This can have implications for the management of electively treated aneurysms, in that these lesions can be treated with the aid of adjunctive devices without the concern that these devices will significantly increase the patient's risk of stroke. Furthermore, altering the procedural anticoagulation regimen in patients with ruptured aneurysms could be considered, and could be accomplished by adding an aspirin to the admission medications or initiating heparinization in the patients at an earlier point in the procedure.
The presence of DW imaging abnormalities has been reported to be as high as 43-61%, even in cases of simple diagnostic angiography. 5, 20, 21 These studies also found higher event rates associated with balloon remodeling, although findings were limited by small population size. In our study we found a much lower overall rate of DW imaging restriction, with a frequency of 24%, despite the fact that patients underwent further intervention. We also grouped DW imaging restriction into findings that were thought to be related to the procedure and those that were thought to be incidental. This is based on the assumption that DW imaging abnormalities related to the treatment procedure would occur only in the treated vascular territory and that such abnormalities in other vascular territories would probably be incidental findings from the diagnostic portion of the study. However, if we include all procedure-related DW imaging changes, the data remain similar, with a frequency of 30%.
There are several limitations to this study. First, this is a retrospective study. Second, there are no preprocedure MR images for comparison. This could result in an artificially high rate of positivity on DW imaging. This is important because there is some evidence that aneurysms alone can cause thromboembolic phenomena. 19 Additionally, patients with SAH may also have DW imaging changes, although these changes are often widespread in the cerebral cortex and tend to be associated with high-grade SAH (World Federation of Neurosurgical Societies Grade IV or V). 10 The clinically evident strokes were determined by chart review. A much stronger method would have been formal pre-and postprocedure assessments performed using the National Institutes of Health Stroke Scale. Another limitation to this study is the fact that patients who have SAH, especially those in higher grades, are very difficult to evaluate for clinical signs of stroke. Also, we incorporated all of our treated patients into this study except for those in whom MR images were not available. The patients who did not undergo follow-up imaging were, for the most part, too unstable or had other considerations, such as hardware that precluded MR imaging. Nonetheless, this would have only strengthened the data supporting the hypothesis that urgently treated aneurysms were associated with higher positivity rates on DW imaging and that the use of adjunctive devices did not increase the rate of DW imaging positivity. Finally, the limited number of patients in the electively treated subgroup precludes meaningful statistical comparison of the cases by procedure, although there is a trend toward recognizing that procedures that include the use of stents have a higher frequency of DW imaging change. It would be important in the future to compile more of these cases and analyze this group.
Clinical evidence of infarction is relatively rare compared with DW imaging changes: 8.4% compared with 24%. Some authors have proposed using DW imaging data to help evaluate procedures and to improve safety. 5 Our data support the contention that DW imaging changes do not necessarily translate into a clinically meaningful measure. 4, 20, 23 Furthermore, endovascular treatment of aneurysms does not result in a high frequency of clinically relevant thromboembolic events; these were found to occur in only 8.4% of cases.
Conclusions
Use of adjunctive devices in treating aneurysms does not appear to increase the frequency of thromboembolic events. The presence of DW imaging abnormalities and clinically evident stroke was actually less in the following situations: 1) when adjunctive devices were used; and 2) in electively treated cases. This was probably related to perioperative antiplatelet medical management. Finally, the presence of DW imaging abnormalities does not necessarily translate into the presence of a clinically apparent stroke.
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